Latest Cordis Stories
Research reveals an aging population and increasing obesity rates fuel the €1.1 Billion dollar Endovascular devices market in Europe. (PRWEB) September 11,
Survey Reveals Most Cardiologists Would Use a Bioabsorbable Stent for Coronary Angioplasty According to iData Research Vancouver, BC (PRWEB) February 15, 2012
NEW BRUNSWICK, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by its subsidiary, Cordis Corporation.
BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists.
PARIS, May 16, 2011 /PRNewswire/ -- Cordis announces the launch in Europe of Radial Solutions, a complete portfolio for transradial interventions.
PARIS, May 16, 2011 /PRNewswire/ -- - Cordis Continues its History of Innovation With Two New Products: EMPIRA(TM) and RADIALSOURCE(TM) Cordis announced it has obtained CE mark for its EMPIRA(TM) and EMPIRA(TM) NC RX PTCA* Dilatation Catheters for the treatment of coronary artery disease.
MARSHALL, Texas, Jan. 28, 2011 /PRNewswire/ -- A federal jury in Marshall, Texas has returned a $482 million verdict for Dickstein Shapiro LLP client Dr. Bruce N. Saffran against defendants Johnson & Johnson and its subsidiary, Cordis Corporation, in Saffran v.
WATERLOO, Belgium, September 30, 2010 /PRNewswire/ -- - SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Clinical Safety and Efficacy Measures With Both CYPHER(R) Stent and XIENCE V(R) Stent - Only CYPHER Stent has More Than 10 years of Clinical Safety Data in 70 Studies Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary...
STOCKHOLM, September 2, 2010 /PRNewswire/ -- - Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT...
- To give a box on the ear to.